The European Medicines Agency validated the Marketing Authorization Application of the fixed-dose combination of Opdivo (nivolumab) and relatlimab, a LAG-3-blocking antibody, for first-line treatment of adult and pediatric patients (12 years and older and weighing at least 40 kg) with advanced, unresectable or metastatic melanoma.
The MD Anderson Cancer Center and Schrödinger, Inc. today announced a two-year strategic research collaboration focused on the development of Schrödinger’s WEE1 inhibitor program, an investigational therapeutic approach designed to target the WEE1 kinase.
NEXT Oncology and Virginia Cancer Specialists have joined forces, launching NEXT Virginia, a cancer clinic, in September 2021.
The National Cancer Institute approved the following clinical research studies last month.
Martin “Mac” Cheever, a Fred Hutchinson Cancer Research Center physician-scientist who was a pioneer in the development of immunotherapies, died on Sept. 23 from complications following heart surgery. He was 77. Friends and colleagues note Cheever’s calm demeanor, generosity and wit. As an oncologist, he was respected for his work as one of the first […]
In real time, the Cancer History Project is documenting a growing collection of podcasts in the oncology sphere, focused on oral histories, the history of cancer advocacy, the evolution of treatment, and more.
Women who report sexual misconduct to NIH may find that their complaints have a limited shelf life—these complaints may become null, or at least ineligible for “even a cursory review” once perpetrators cut ties with NIH.
NIH may be “constrained” in investigating sexual misconduct at NIH-funded institutions once alleged perpetrators are no longer affiliated with these institutions, NIH officials implied in their response to a congressional inquiry on sexual misconduct (The Cancer Letter, Sept. 24, 2021).
As we approach the 23rd anniversary of The March, The Cancer Letter archives offer a unique way to reflect on the leadup to—and events of—the day. In October, 1997, The Cancer Letter dedicated the entirety of what was then an 8-page publication to a lengthy analysis of the vision for The March. Then, one year later, those same 8 pages were trained on the event—the speeches, the attendance, the music, and more.
The prevalence of workplace harassment, discrimination, and retaliation experienced by women physicians, especially women of color, is alarmingly high.
